All Oncology News

Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.

Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

The FDA has granted fast track designation to PT217 for patients with extensive stage small cell lung cancer with disease progression.

Mirvetuximab soravtansine plus pembrolizumab displays efficacy in recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer.

Yale Cancer Center will share data for breakthrough and emerging cancer treatments at the AACR Annual Meeting.

Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

The FDA has accepted for review the new drug application for SH-201 for the treatment of patients with certain forms of leukemia and other cancers.

Copanlisib plus nivolumab was active and met the primary end point of a phase 1/2 study in a cohort of patients with MSS CRC.

A microRNA assay combined with CA19-9 displayed diagnostic accuracy in the early detection of pancreatic cancer.

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Administration of atezolizumab after definitive local therapy did not improve EFS or OS in patients with head and neck squamous cell carcinoma.

The FDA has granted breakthrough therapy designation to sunvozertinib for patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation.

Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets

The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.

Dana-Farber details how their Neuro-Inclusive Oncology Care and Empowerment program was developed to help physicians and other providers treat cancer in patients who have intellectual and/or developmental disabilities.

Fifty-seven percent of drugs granted accelerated approval for a cancer indication failed to show clinical benefit in confirmatory studies.

Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.

Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.

In a new phase 3 clinical trial, imetelstat demonstrated clear advantages for patients who have failed or are ineligible for other therapies.

Sanjay S. Reddy, MD, FACS, of Fox Chase Cancer Center was recently chosen as a participant in the Society of Surgical Oncology’s inaugural Career Catalyst Mentorship Program.

Eduardo M. Sotomayor, MD, discusses updates in the treatment of hematologic malignancies, highlighting research on antibody-drug conjugate and bispecific antibody combinations.

The FDA has approved cilta-cel for select patients with relapsed/refractory multiple myeloma who have received at least 1 line of therapy, and who are lenalidomide refractory.

Michael Iglesia, MD, PhD, discusses the effects of the phase 3 CELESTIAL trial on treatment sequencing strategies in advanced hepatocellular carcinoma.

The FDA granted accelerated approval to trastuzumab deruxtecan for pretreated, unresectable or metastatic HER2-positive solid tumors.

Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.

Gita Suneja, MD, MS, has been named the senior director of Programs to Enhance Diversity at Huntsman Cancer Institute.

RNX-051 displays impact on bacterial biomass in patients with right-sided colorectal cancer and right-sided colon polyps/adenomas.